Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29480718 | 0.86 | JAK2 (0.32) | — | |
| SCHEMBL2509709 | 0.79 | PTGS1 (0.35) | PTGS1PTGS2 | |
| SCHEMBL16768778 | 0.77 | — | — | |
| SCHEMBL21761138 | 0.76 | PTGS1 (0.32) | PTGS1PTGS2 | |
| SCHEMBL16000111 | 0.75 | PTGS1 (0.31) | PTGS1PTGS2 | |
| SCHEMBL4922033 | 0.74 | — | — | |
| SCHEMBL8213784 | 0.74 | PGR (0.31) | — | |
| SCHEMBL17452115 | 0.73 | — | — | |
| SCHEMBL12425776 | 0.73 | CA1 (0.44) | PTGS1PTGS2 | |
| SCHEMBL27857677 | 0.73 | PTGS1 (0.31) | PTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220185816-A1 | JAK KINASE INHIBITOR, PREPARATION METHOD FOR SAME, AND APPLICATIONS THEREOF IN FIELD OF MEDICINE | SHANGHAI SYNERGY PHARMACEUTICAL SCIENCES CO., LTD (CN) | 2022-06-16 | — | — | US | disclosed |
| EP-3939979-A1 | JAK KINASE INHIBITOR, PREPARATION METHOD FOR SAME, AND APPLICATIONS THEREOF IN FIELD OF MEDICINE | Shanghai Synergy Pharmaceutical Sciences Co., Ltd (CN) | 2022-01-19 | — | — | EP | disclosed |
| WO-2020182159-A1 | JAK KINASE INHIBITOR, PREPARATION METHOD FOR SAME, AND APPLICATIONS THEREOF IN FIELD OF MEDICINE | 上海华汇拓医药科技有限公司 | 2020-09-17 | — | — | WO | disclosed |
| US-9199959-B2 | HIV replication inhibitor | SHIONOGI & CO., LTD. (JP) | 2015-12-01 | — | — | US | disclosed |
| US-20140249306-A1 | HIV REPLICATION INHIBITOR | SHIONOGI & CO., LTD. (JP) | 2014-09-04 | — | — | US | disclosed |
| US-20120165309-A1 | HETERO RING DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2012-06-28 | — | — | US | disclosed |
| EP-2397479-A1 | HETERO RING DERIVATIVE | Astellas Pharma Inc. (JP) | 2011-12-21 | — | — | EP | disclosed |
| WO-2010092962-A1 | HETERO RING DERIVATIVE | アステラス製薬株式会社 (JP) | 2010-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165309-A1 | HETERO RING DERIVATIVE | IL2, PIK3R2, IL2RA | PTGS1 1076/4885PTGS2 137/4885 |
| US-20140249306-A1 | HIV REPLICATION INHIBITOR | SSU72, RTF2, ZC3HAV1 | PTGS1 3702/4885PTGS2 3922/4885 |
| US-20220185816-A1 | JAK KINASE INHIBITOR, PREPARATION METHOD FOR SAME, AND APPLICATIONS THEREOF IN FIELD OF MEDICINE | JAK1, JAK2, JAK3 | PTGS1 465/4885PTGS2 325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.